Related Experiment Video
Updated: Oct 28, 2026

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
Published on: November 21, 2012
Mechanisms of vesicular monoamine transporter 2 modulation by amphetamines and lobeline
Di Wu1, Chuanyu Liu1, Hongshuang Wang2
1Beijing National Laboratory for Condensed Matter Physics, Laboratory of Soft Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100190, China.
Abstract:
Amphetamine-type stimulants (ATSs) disrupt the brain monoaminergic system and strongly stimulate motivation, movement, and addiction. Vesicular monoamine transporter 2 (VMAT2) plays a vital role in monoaminergic neurotransmission by sequestering monoamines in presynaptic vesicles. How ATS binds to and regulates VMAT2 remains elusive. Here, we report the cryo-EM structures of human VMAT2 in complex with four ATSs (AMPH, METH, MDMA, and MDA) and the inhibitor lobeline, revealing the molecular mechanisms underlying ATS recognition and modulation. ATSs mimic monoamines and occupy the substrate-binding site of VMAT2, indicating that ATSs function as substrates and thus redistribute the vesicular monoamine pools to the cytosolic pools. Lobeline adopts an unexpected dual-binding mode and locks VMAT2 in a lumen-facing conformation, inhibiting monoamine and ATS uptake. Our dopamine release assay revealed that lobeline regulates AMPH-induced dopamine release by modulating both VMAT2 and DAT. This study provides important mechanistic insights into VMAT2 modulation by amphetamines and lobeline.
More Related Videos
07:56A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
11:26Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
Published on: September 21, 2017
Related Concept Videos
Drugs Affecting Neurotransmitter Release or Uptake
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Neurochemical Transmission: Sites of Drug Action
Drugs Affecting Neurotransmitter Synthesis
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists